Cat. No.: HY-B0413

Fenbendazole

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 43210-67-9
Formula: C₁₅H₁₃N₃O₂S
Molecular Weight:299.35

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Fenbendazole Chemical Structure

CAS No.: 43210-67-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Parasite Isoforms :

All HIF/HIF Prolyl-Hydroxylase Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	3 x 10⁴ nM Compound: Fenbendazole	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HepG2	EC₅₀	10 μM Compound: Fenbendazole	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	4 μM Compound: Fenbendazole	Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
PC-3M	EC₅₀	2.6 μM Compound: Fenbendazole	Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay	[PMID: 29288939]

In Vitro

Fenbendazole (1 uM; for 24 h) significantly reduces cell growth in tumour cell lines with wild-type p53, H460 and A549 human NSCLC cell lines^[1].
Fenbendazole (1 uM; for 24 h) induces apoptosis and causes an increased level of p53 protein in the mitochondrial fraction^[1].
Fenbendazole (1 uM; for 24 h) causes cell cycle arrest in the mitotic phase in human NSCLC cells^[1].
Fenbendazole (1 uM; for 24 h) causes a partial alteration of the microtubule network in human non small cell lung carcinoma (NSCLC) A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

A549 cells
Concentration:

1 uM
Incubation Time:

For 24 h
Result:

Caused an early elevation of cyclin B1/CDK1 levels (8 h as compared to 16 h in case of control untreated cells).
p-histone H3 (Ser10) was found to be up-regulated at 12 and 24 h.

Apoptosis Analysis^[1]

Cell Line:

A549 cells
Concentration:

1 uM
Incubation Time:

8, 16, 24, 32, 40, 48 h
Result:

The number of apoptotic cells increased in a time dependent manner with simultaneous decrease in cyclin B1 levels, and ~30% cells had undergone apoptosis after 32 h.

Western Blot Analysis^[1]

Cell Line:

H460 cells
Concentration:

1 uM
Incubation Time:

For 24 h
Result:

Caused an increased level of p53 protein in the mitochondrial fraction.

In Vivo

Fenbendazole (1 mg; orally; every second day for 12 day) leads to a marked reduction in tumour size and weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female athymic nu/nu mice were xenografted with A549 cells^[1]
Dosage:

1 mg/mouse
Administration:

Orally; every second day for 12 day
Result:

Led to a marked reduction in tumour size and weight.
Led to a reduction in hemoglobin content in tumors signifying reduced tumor vascularity.

Chemical Information

CAS No. 43210-67-9
Appearance Solid
Molecular Weight 299.35
Formula C₁₅H₁₃N₃O₂S
Color White to off-white
SMILES

O=C(OC)NC1=NC2=CC=C(SC3=CC=CC=C3)C=C2N1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All RT-PCRWBCell Imaging/StainingCell Proliferation/Viability AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Redox Rep

HIF1A/BNIP3 pathway affects ferroptosis in sepsis-induced cardiomyopathy through binding to BCL-2. [Abstract]

2025 Dec;30(1):2544412. PMID: 40779707

Fenbendazole purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2544412. [Abstract]

Quantification of HIF1A and BNIP3 mRNA levels using qRT-PCR. Fenbendazole (FZ; 1 μM; 48 h) increased HIF1A and BNIP3 mRNA levels.

Fenbendazole purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2544412. [Abstract]

Western blot analysis of HIF1A/BNIP3 pathway protein expression in H9c2 cardiomyocytes. Fenbendazole (FZ; 1 μM; 48 h) further increased HIF1A and BNIP3 protein levels compared with LPS alone.

Fenbendazole purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2544412. [Abstract]

Fenbendazole (FZ; 1 μM; 48 h). Detection of intracellular ROS in H9c2 cells using DHE staining.

Fenbendazole purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2544412. [Abstract]

Cell viability was assessed by CCK-8 assay in H9c2 cardiomyocytes after FZ (Fenbendazole; 1 μM; 48 h) treatment. CCK-8 assays showed decreased viability in LPS and LPS + FZ groups.

Fenbendazole purchased from MedChemExpress. Usage Cited in: Redox Rep. 2025 Dec;30(1):2544412. [Abstract]

Fe²⁺, MDA, and GSH levels were measured in lysates of H9c2 cardiomyocytes after FZ treatment (Fenbendazole; 1 μM; 48 h). Fe²⁺ and MDA levels were elevated by LPS/FZ and reduced by LW6 or BNIP3 silencing; GSH depletion was likewise reversed.
Commun Biol

Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. [Abstract]

2024 Jan 24;7(1):123. PMID: 38267545
J Pathol

Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities. [Abstract]

2023 Jun;260(2):203-221. PMID: 36825655
Molecules

Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening. [Abstract]

2026 Mar 5;31(5):864. PMID: 41828851
J Vet Sci

Dewormer drug fenbendazole has antiviral effects on BoHV-1 productive infection in cell cultures. [Abstract]

2020 Sep;21(5):e72. PMID: 33016019
Research Square Preprint

2021 Aug.

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (33.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3406 mL

16.7029 mL

33.4057 mL

5 mM

0.6681 mL

3.3406 mL

6.6811 mL

10 mM

0.3341 mL

1.6703 mL

3.3406 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (3.34 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (3.34 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (563 KB)
- English - EN (563 KB)
- Français - FR (563 KB)
- Deutsch - DE (563 KB)
- Norwegian - NO (563 KB)
- Español - ES (563 KB)
- Swedish - SV (563 KB)
- Italian - IT (563 KB)
- Korean - KR (563 KB)
- Portuguese - PT (563 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8(1):11926. [Content Brief]

[2]. Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. [Content Brief]

[3]. Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb;33(2):355-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3406 mL	16.7029 mL	33.4057 mL	83.5143 mL
	5 mM	0.6681 mL	3.3406 mL	6.6811 mL	16.7029 mL
	10 mM	0.3341 mL	1.6703 mL	3.3406 mL	8.3514 mL
	15 mM	0.2227 mL	1.1135 mL	2.2270 mL	5.5676 mL
	20 mM	0.1670 mL	0.8351 mL	1.6703 mL	4.1757 mL
	25 mM	0.1336 mL	0.6681 mL	1.3362 mL	3.3406 mL
	30 mM	0.1114 mL	0.5568 mL	1.1135 mL	2.7838 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Fenbendazole

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Fenbendazole

All Parasite Isoforms

All HIF/HIF Prolyl-Hydroxylase Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (8)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Fenbendazole Related Classifications

HY-B0413 Related Classifications